NCT00547586View on ClinicalTrials.gov

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Constipation
Interventions
DRUG

N-methylnaltrexone bromide (MOA-728)

Oral

OTHER

placebo

placebo

Trial Locations (41)

2301

Brockton

21075

Elkridge

22304

Alexandria

27103

Winston-Salem

28204

Charlotte

30060

Murrieta

32174

Ormond Beach

32216

Jacksonville

32626

Chiefland

33458

Jupiter

33770

Largo

34104

Naples

34471

Ocala

34609

Spring Hill

36608

Mobile

37404

Chattanooga

39531

Biloxi

39564

Ocean Springs

43623

Toledo

45439

Dayton

46250

Indianapolis

49601

Cadillac

49684

Traverse City

60610

Chicago

70584

Sunset

71901

Hot Springs

71903

Hot Springs

75230

Dallas

76034

Colleyville

77701

Beaumont

78229

San Antonio

85340

Litchfield Park

85710

Tucson

85741

Tucson

87102

Albuquerque

89119

Las Vegas

90048

Los Angeles

90813

Long Beach

92121

San Diego

92843

Garden Grove

97504

Medford

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00547586 - Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain | Biotech Hunter | Biotech Hunter